Our results further showed that P2pal-18S potentiated gefitinib inhibition in phosphorylation of ERK, suggesting that targeting PAR2 may inhibit EGFR transactivation and ERK activation to reverse gefitinib resistance in NSCLC (Figures 3B,C). Here, F2RL1 is linked to non-small cell lung carcinoma.